Cargando…

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinetti, Antonia, Miceli, Rosalba, Sottotetti, Elisa, Di Bartolomeo, Maria, de Braud, Filippo, Gevorgyan, Arpine, Dotti, Katia Fiorella, Bajetta, Emilio, Campiglio, Manuela, Bianchi, Francesca, Bregni, Giacomo, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/
https://www.ncbi.nlm.nih.gov/pubmed/25256831
http://dx.doi.org/10.3390/cancers6031753
_version_ 1782338538544562176
author Martinetti, Antonia
Miceli, Rosalba
Sottotetti, Elisa
Di Bartolomeo, Maria
de Braud, Filippo
Gevorgyan, Arpine
Dotti, Katia Fiorella
Bajetta, Emilio
Campiglio, Manuela
Bianchi, Francesca
Bregni, Giacomo
Pietrantonio, Filippo
author_facet Martinetti, Antonia
Miceli, Rosalba
Sottotetti, Elisa
Di Bartolomeo, Maria
de Braud, Filippo
Gevorgyan, Arpine
Dotti, Katia Fiorella
Bajetta, Emilio
Campiglio, Manuela
Bianchi, Francesca
Bregni, Giacomo
Pietrantonio, Filippo
author_sort Martinetti, Antonia
collection PubMed
description The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma samples from 50 patients treated at a single Institution were analysed using the multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) at baseline, before first three cycles and subsequently every three cycles until disease progression. Prognostic analyses of baseline values were performed using multivariable Cox models, including disease extension >10 cm or ≤10 cm (measured as the sum of the diameters for all target lesions) as adjustment factor. The association between progression-free and overall survival and biomarkers modulation during treatment was studied using multivariable Cox models, which included summary statistics synthesizing during-treatment modulation together with disease extension. The biomarkers significantly associated with disease extension were baseline CEA (p = 0.012) and SDF-1 (p = 0.030). High values of VEGF and SDF-1 tended to be associated with worse prognosis, especially in terms of overall survival. The negative prognostic trend was more marked for baseline CEA as compared to other biomarkers; increasing values during treatment was significantly related to worse prognosis independently of disease extension (p = 0.007 and 0.016 for progression-free and overall survival, respectively). VEGF is related to bevacizumab pharmacodynamics and is associated to other angiogenic cytokines; some of the proposed biomarkers such as SDF-1 and CEA should be further validated for prognosis assessment and monitoring of bevacizumab-based treatment of advanced colorectal cancer.
format Online
Article
Text
id pubmed-4190566
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-41905662014-10-09 Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens Martinetti, Antonia Miceli, Rosalba Sottotetti, Elisa Di Bartolomeo, Maria de Braud, Filippo Gevorgyan, Arpine Dotti, Katia Fiorella Bajetta, Emilio Campiglio, Manuela Bianchi, Francesca Bregni, Giacomo Pietrantonio, Filippo Cancers (Basel) Article The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma samples from 50 patients treated at a single Institution were analysed using the multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) at baseline, before first three cycles and subsequently every three cycles until disease progression. Prognostic analyses of baseline values were performed using multivariable Cox models, including disease extension >10 cm or ≤10 cm (measured as the sum of the diameters for all target lesions) as adjustment factor. The association between progression-free and overall survival and biomarkers modulation during treatment was studied using multivariable Cox models, which included summary statistics synthesizing during-treatment modulation together with disease extension. The biomarkers significantly associated with disease extension were baseline CEA (p = 0.012) and SDF-1 (p = 0.030). High values of VEGF and SDF-1 tended to be associated with worse prognosis, especially in terms of overall survival. The negative prognostic trend was more marked for baseline CEA as compared to other biomarkers; increasing values during treatment was significantly related to worse prognosis independently of disease extension (p = 0.007 and 0.016 for progression-free and overall survival, respectively). VEGF is related to bevacizumab pharmacodynamics and is associated to other angiogenic cytokines; some of the proposed biomarkers such as SDF-1 and CEA should be further validated for prognosis assessment and monitoring of bevacizumab-based treatment of advanced colorectal cancer. MDPI 2014-08-29 /pmc/articles/PMC4190566/ /pubmed/25256831 http://dx.doi.org/10.3390/cancers6031753 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Martinetti, Antonia
Miceli, Rosalba
Sottotetti, Elisa
Di Bartolomeo, Maria
de Braud, Filippo
Gevorgyan, Arpine
Dotti, Katia Fiorella
Bajetta, Emilio
Campiglio, Manuela
Bianchi, Francesca
Bregni, Giacomo
Pietrantonio, Filippo
Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title_full Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title_fullStr Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title_full_unstemmed Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title_short Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
title_sort circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/
https://www.ncbi.nlm.nih.gov/pubmed/25256831
http://dx.doi.org/10.3390/cancers6031753
work_keys_str_mv AT martinettiantonia circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT micelirosalba circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT sottotettielisa circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT dibartolomeomaria circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT debraudfilippo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT gevorgyanarpine circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT dottikatiafiorella circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT bajettaemilio circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT campigliomanuela circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT bianchifrancesca circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT bregnigiacomo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens
AT pietrantoniofilippo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens